C12N2840/007

CNS targeting AAV vectors and methods of use thereof

The invention in some aspects relates to recombinant adeno-associated viruses useful for targeting transgenes to CNS tissue, and compositions comprising the same, and methods of use thereof. In some aspects, the invention provides methods and compositions for treating CNS-related disorders.

GENE EXPRESSION SYSTEM
20170188559 · 2017-07-06 · ·

Two or more conditional, dominant, lethal gene expression systems provide high levels of penetrance in insects. Lethality is induced at an earlier stage of development and the risk of biochemical resistance is reduced, as compared to a single insect conditional, dominant, lethal gene expression system. The invention is useful for the control of insect populations.

ISOLATION OF NOVEL AAV'S AND USES THEREOF

The invention in some aspects relates to isolated nucleic acids, compositions, and kits useful for identifying adeno-associated viruses in cells. In some aspects, the invention provides kits and methods for producing somatic transgenic animal models using recombinant AAV (rAAV) to an animal having at least one transgene that expresses a small interfering nucleic acid or at least one binding site for a miRNA.

ISOLATION OF NOVEL AAV'S AND USES THEREOF

The invention in some aspects relates to isolated nucleic acids, compositions, and kits useful for identifying adeno-associated viruses in cells. In some aspects, the invention provides kits and methods for producing somatic transgenic animal models using recombinant AAV (rAAV) to an animal having at least one transgene that expresses a small interfering nucleic acid or at least one binding site for a miRNA.

EFFICIENT SYSTEMIC TREATMENT OF DYSTROPHIC MUSCLE PATHOLOGIES

A composition comprising a gene therapy product for use in the treatment of a dystrophic disease in a subject, advantageously in humans, wherein:the gene therapy product comprises a nucleic acid sequence encoding a functional microdystrophin;the composition is systemically administered.

Methods of treating non-syndromic sensorineural hearing loss
12226493 · 2025-02-18 · ·

Provided herein are compositions that include at least two different nucleic acid vectors, where each of the at least two different vectors includes a coding sequence that encodes a different portion of a stereocilin protein, and the use of these compositions to treat non-syndromic sensorineural hearing loss in a subject.

NPP1 FUSION PROTEINS
20170145393 · 2017-05-25 ·

The present invention provides a novel fusion polypeptide containing a catalytic domain of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.

Isolation of novel AAV's and uses thereof

The invention in some aspects relates to isolated nucleic acids, compositions, and kits useful for identifying adeno-associated viruses in cells. In some aspects, the invention provides kits and methods for producing somatic transgenic animal models using recombinant AAV (rAAV) to an animal having at least one transgene that expresses a small interfering nucleic acid or at least one binding site for a miRNA.

VECTOR CONSTRUCTS FOR DELIVERY OF NUCLEIC ACIDS ENCODING THERAPEUTIC ANTI-IGF-1R ANTIBODIES AND METHODS OF USING THE SAME

The present disclosure provides gene therapy vectors, antibody expression cassettes, and vectors comprising a nucleic acid encoding a therapeutic anti-IGF-1R antibody (e.g., a monoclonal antibody) or an antigen binding fragment thereof, delivery vectors (e.g., viral vectors) comprising gene therapy constructs a nucleic acid encoding a therapeutic anti-IGF-1R antibody (e.g., a monoclonal antibody) or an antigen binding fragment thereof, compositions comprising the same, and methods of using the same. Some aspects of the disclosure are directed to a recombinant adeno-viral vector (rAAV) particle for delivery of a nucleic acid encoding a therapeutic anti-IGF-1R antibody (e.g., a monoclonal antibody) or an antigen binding fragment thereof.

METHODS AND COMPOSITIONS RELATING TO THE TREATMENT OF TUMORS

Described herein are methods and compositions relating to the treatment of a tumor (e.g., schwannoma) by increasing expression of Apoptosis-associated Speck-like protein containing a CARD (ASC) and/or gasdermin D. In some embodiments, the increased expression is provided by means of a vector or construct comprising a nucleic acid encoding Apoptosis-associated Speck-like protein containing a CARD (ASC) and/or gasdermin D operably linked to a Schwann-lineage cell-specific promoter. In some embodiments, the vector is a viral vector.